AstraZeneca full-year earnings: Can the pharma giant maintain oncology momentum?
AstraZeneca reports full-year 2025 results on 10 February, with investors focused on oncology growth, pipeline progress and margin sustainability across franchises.
AstraZeneca full-year earnings: can the pharma giant maintain oncology momentum?
AstraZeneca is set to release its full-year 2025 (FY25) financial results on 10 February 2026, a milestone moment for one of the world's largest biopharmaceutical companies.
The upcoming report will provide a comprehensive view of how AstraZeneca performed across its key therapeutic franchises, how effectively it navigated competitive and regulatory challenges, and how well it is positioned to translate a strong late-stage pipeline into sustainable growth.
AstraZeneca FY 2025 financial expectations:
AstraZeneca is expected to report solid revenue and earnings per share (EPS) growth but a slightly lower pre-tax profit.
- Revenue: £58.64 billion, 8.4% above its FY 2024 £54.07 billion result
- Pre-tax profit: £15.53 billion, slightly lower compared to a year ago
- EPS: 9.12 pence, up around 11% compared to the previous year
Revenue growth across therapeutic franchises
Investors will be looking first and foremost at revenue growth, particularly in high-value segments such as Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory & Immunology (R&I).
AstraZeneca's most recent quarterly and interim results signalled continued momentum in Oncology, with strong uptake of key therapies such as Tagrisso (for EGFR-mutated non-small cell lung cancer), Enhertu (HER2-targeted therapy) and combination regimens that are expanding the company's addressable patient populations.
The upcoming full-year results will clarify whether these trends held through the fourth quarter (Q4) and translated into a full-year oncology growth rate that meets or exceeds consensus expectations.
Oncology represents AstraZeneca's largest and fastest-growing therapeutic area.
Tagrisso has become one of the pharmaceutical industry's most successful targeted cancer therapies. Its expansion into adjuvant treatment settings beyond advanced disease has substantially increased the addressable patient population.
Enhertu, developed through partnership with Daiichi Sankyo, demonstrates AstraZeneca's collaborative approach to oncology drug development. The therapy's label expansions across multiple HER2-positive cancers drive continued growth.
CVRM and respiratory franchises drive diversification
Cardiovascular, renal and metabolism (CVRM) and respiratory and immunology (R&I) also remain crucial pillars of AstraZeneca's long-term strategy beyond oncology.
Products such as Farxiga (SGLT2 inhibitor for heart failure and chronic kidney disease) have continued to penetrate new markets and indications, contributing to robust double-digit growth in these therapy areas.
Analysts will pay close attention to whether these engines of growth maintained strong year-end momentum, particularly given pricing and reimbursement pressures in key regions such as the United States (US) and parts of Europe.
Key product performance to monitor
Several specific products will drive revenue assessment:
- Tagrisso oncology franchise sales and market share
- Enhertu uptake across approved indications
- Farxiga growth in cardiovascular and renal markets
- Imfinzi oncology sales and label expansion benefits
- Respiratory products performance amid competitive pressures
Profitability and margin discipline
Profitability and margins will be another focus of the 10 February 2026 release and critical for assessing earnings quality.
AstraZeneca has historically maintained a disciplined approach to R&D investment, balancing near-term margin pressure with long-term pipeline potential.
Operating margins and adjusted EPS will be scrutinised for signs that the company is not only growing revenue but also converting that growth into sustainable bottom-line performance.
Cost control in commercial operations and R&D efficiency - particularly in late-stage clinical programmes - will influence investor confidence in margin guidance for 2026.
Cash generation and capital allocation
Cash flows and capital allocation are additional themes likely to shape market reaction to results. AstraZeneca has typically delivered strong free cash flow, enabling it to support dividend payments and opportunistic share buybacks while funding its pipeline.
Any commentary on future dividend increases, share repurchase intent or the timing of milestone-dependent payments to partners will be relevant to income-oriented investors.
Pipeline developments and regulatory catalysts
Pipeline development and regulatory catalysts are key strategic drivers beyond current product performance.
AstraZeneca has a deep late-stage portfolio, including potential blockbusters in oncology, cardiovascular and rare diseases.
Investors will watch for news on regulatory approvals, label expansions and late-stage trial outcomes that could materially impact future growth. Any updates on progress toward regulatory submissions or enrolment milestones in high-impact trials will likely attract attention alongside the financials.
Geographic diversification and pricing pressures
Geographic performance and pricing dynamics remain important considerations for assessing sustainable growth. With a broad global footprint, AstraZeneca must navigate a wide range of healthcare systems, pricing pressures and reimbursement environments.
Commentary on relative performance in the US, Europe, China and emerging markets will help frame investor expectations for regional diversification and growth sustainability.
The US represents the world's largest pharmaceutical market with premium pricing but faces increasing political pressure around drug costs.
China has become increasingly important for pharmaceutical companies given its large population and growing healthcare spending. However, regulatory requirements and pricing pressures create unique challenges.
Regional revenue dynamics
AstraZeneca's geographic exposure includes:
- US (largest single market, premium pricing)
- Europe (multiple markets with varying reimbursement systems)
- China (high-growth market with volume-based procurement)
- Japan (aging population, established pharmaceutical market)
- Emerging markets (growth opportunities with affordability challenges)
Competitive landscape in biopharmaceuticals
Understanding AstraZeneca's results requires viewing them within the broader pharmaceutical sector context. The company competes with Roche, Merck, Bristol Myers Squibb and others across oncology and other therapeutic areas.
Oncology competition has intensified with numerous novel mechanisms and combination approaches entering development. AstraZeneca must differentiate products through clinical superiority, commercial execution or pricing strategies.
Cardiovascular and metabolic medicine markets face competition from established therapies and new entrants. SGLT2 inhibitors like Farxiga compete against other drug classes for treatment guidelines positioning.
The FTSE 100 includes both AstraZeneca and GlaxoSmithKline (GSK), making pharmaceutical sector performance relevant for UK equity index returns.
What the full-year results mean for investors
In summary, AstraZeneca's 10 February 2026 full-year results will be a critical assessment of whether the company's strong product franchises, pipeline momentum and execution discipline are delivering top-line growth and bottom-line resilience.
A robust earnings print, with sustained growth across core therapy areas and constructive guidance for 2026, would reinforce confidence in AstraZeneca's strategic trajectory.
Conversely, signs of slowing demand in major product lines, margin compression or a lack of visibility on future catalysts could temper sentiment in an increasingly competitive biotech landscape. The market will particularly scrutinise oncology performance given this franchise's strategic importance.
AstraZeneca analyst ratings and technical analysis
Fundamental analysts rate AstraZeneca as a ’buy’, with a long-term consensus price target of 14,812.75p, approximately 7% above current levels as of 4 February 2026.
AstraZeneca LSEG Data & Analytics chart
AstraZeneca has a TipRanks Smart Score of “9 - Outperform” and a ‘strong buy’ rating.
AstraZeneca TipRanks Smart Score chart
Technical analysis of the AstraZeneca share price
AstraZeneca’s shares have risen by less than 1% since the beginning of the year and by around 24% over the past year.
The shares’ upside is currently being capped by its November-to-January record highs at 14,206p - 14,408p.
AstraZeneca daily candlestick chart
While the January low at 13,268p holds on a daily chart closing basis, though, the medium-term uptrend is deemed to stay intact with the 15,000p mark remaining in focus.
Support below the 20 January 13,268p low may be seen between the October high and early November low at 12,972p - 12,240p.
How to invest in AstraZeneca shares
Investors interested in pharmaceutical sector exposure through AstraZeneca have several options. Here's how to approach investing in this global biopharmaceutical company:
- Research AstraZeneca's latest results, pipeline developments and pharmaceutical industry trends thoroughly. Understanding drug development, regulatory processes and healthcare market dynamics helps inform investment decisions. How to invest in stocks provides useful background.
- Download IG Invest or open a share dealing account to access UK-listed shares. AstraZeneca trades on the London Stock Exchange under the ticker AZN.
- Search for AstraZeneca PLC shares on the trading platform. Review current pricing, dividend yields and analyst recommendations before making investment decisions.
- Choose the number of shares or value of money you'd like to invest based on your portfolio allocation strategy. Consider whether to hold shares in a general account, individual savings account (ISA) or self-invested personal pension (SIPP) for tax efficiency.
- Place your trade and monitor your investment over time. AstraZeneca provides quarterly results and regular pipeline updates, offering insight into operational and financial performance.
Remember that pharmaceutical stocks face regulatory, competitive and patent expiry risks. Diversification across multiple sectors reduces concentration risk whilst maintaining exposure to pharmaceutical innovation and healthcare growth trends.
Important to know
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Connect with us
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Professional clients trading spread bets and CFDs can lose more than they deposit.
The value of shares, ETFs and other ETPs bought through a share dealing account, a stocks and shares ISA or a SIPP can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results. Some ETPs carry additional risks depending on how they’re structured, investors should ensure they familiarise themselves with the differences before investing.
Share dealing and IG Smart Portfolio accounts provided by IG Trading and Investments Ltd, CFD accounts and futures accounts are provided by IG Markets Ltd, spread betting provided by IG Index Ltd.
IG is a trading name of IG Trading and Investments Ltd (a company registered in England and Wales under number 11628764), IG Markets Ltd (a company registered in England and Wales under number 04008957) and IG Index Ltd (a company registered in England and Wales under number 01190902). Registered address at Cannon Bridge House, 25 Dowgate Hill, London EC4R 2YA. IG Markets Ltd (Register number 195355), IG Trading and Investments Ltd (Register Number 944492) and IG Index Ltd (Register number 114059) are authorised and regulated by the Financial Conduct Authority.
The information on this site isn’t directed at residents of the United States, Belgium or any particular country outside the UK and isn’t intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
